Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health
The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.
Image Credit: Adobe Stock Images/Jordan
Sen-Jam Pharmaceutical announced that it has received an investment from 5 Horizons Capital to advance a Phase II clinical trial for SJP-001, a novel therapy for inflammation and metabolic health. The trial, which was developed in collaboration with Novotech, will evaluate SJP-001’s potential to improve metabolic health, specifically targeting dietary and alcohol-induced overindulgence. Additionally, the partnership is expected to combine Sen-Jam’s technology, Novotech’s expertise in early phase clinical trials, and 5 Horizons’ financial and strategic resources to accelerate the therapeutic’s development, the companies stated in a press release.1
"We are thrilled to welcome 5 Horizons Capital as a financial and strategic partner to our team, on our journey to revolutionize inflammation care. Their investment and expertise in advancing clinical-stage therapies will enable us to bring SJP-001 closer to patients worldwide. With Novotech's excellence in trial management and 5 Horizons' visionary support, we are one step closer to transforming how the world addresses metabolic health and inflammation,” said Jim Iversen, co-founder, CEO, Sen-Jam Pharmaceutical, in a press release.
A pilot study sought to determine the effects of SJP-001 on alcohol hangover severity. Thirteen healthy social drinkers participated in the double-blind, factorial design, crossover study, with each participant consuming their preferred amount of alcohol sufficient enough to report a hangover on a daily basis. Each morning, hangover severity was assessed with the Acute Hangover Scale (AHS).
Results found that SJP-001 significantly improved the AHS overall hangover severity score compared to placebo. Additionally, the treatment demonstrated improvements on hangover scores; however, the observed improvement didn’t reach clinical significance. The treatment improved scores for symptoms such as tiredness, thirst, headache, dizziness, nausea, and loss of appetite, but these also didn’t reach statistical significance.2
"As the lead investor in Sen-Jam's Phase 2 clinical trial for SJP-001, we are proud to be part of this community that has the potential to redefine how inflammation is treated globally. We are committed to supporting this groundbreaking therapeutic as it moves into clinical trials. Additionally, we look forward to collaborating with other investors to drive follow-on funding and accelerate the development of this promising asset,” said Aaron Ray, managing director, 5 Horizons Capital, in the press release.
References
1. Sen-Jam Pharmaceutical Secures Financial and Strategic Investment from 5 Horizons Capital to Advance SJP-001 Clinical Trial with Novotech. PR Newswire. January 22, 2025. Accessed January 22, 2025. https://www.prnewswire.com/news-releases/sen-jam-pharmaceutical-secures-financial-and-strategic-investment-from-5-horizons-capital-to-advance-sjp-001-clinical-trial-with-novotech-302357405.html
2. The Effects of SJP-001 on Alcohol Hangover Severity: A Pilot Study. PubMed. Accessed January 22, 2025. https://pubmed.ncbi.nlm.nih.gov/32244274/
Odylia Rare Disease Day Event Highlights Challenges in R&D for Orphan Drugs
April 14th 2025Odylia Therapeutics event brings together leaders across biotech, pharma, venture capital, patient advocacy, and research sectors to address the financial and structural barriers that impede rare disease drug development.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
